This learning plan is based on IRIS Registry measure IRIS45: Exudative Age-Related Macular Degeneration: Loss of Visual Acuity. The plan reviews the impact of anti-vascular endothelial growth factor (anti-VEGF) injections in patients with wet age-related macular degeneration (AMD), including genetic predictive biomarkers of anti-VEGF treatment responses.

  Funded in part by the Retina Research Foundation